Altavista Wealth Management Inc. decreased its position in shares of Pfizer Inc. (NYSE:PFE) by 2.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 30,059 shares of the biopharmaceutical company’s stock after selling 843 shares during the period. Altavista Wealth Management Inc.’s holdings in Pfizer were worth $976,000 as of its most recent filing with the SEC.
Other hedge funds and other institutional investors also recently modified their holdings of the company. Fusion Family Wealth LLC acquired a new stake in Pfizer during the fourth quarter worth $109,000. First National Bank Sioux Falls raised its stake in Pfizer by 108.2% in the third quarter. First National Bank Sioux Falls now owns 3,367 shares of the biopharmaceutical company’s stock worth $114,000 after buying an additional 1,750 shares during the last quarter. Gierl Augustine Investment Management Inc raised its stake in Pfizer by 5.8% in the third quarter. Gierl Augustine Investment Management Inc now owns 3,718 shares of the biopharmaceutical company’s stock worth $126,000 after buying an additional 205 shares during the last quarter. Stanford Investment Group Inc. raised its stake in Pfizer by 11.8% in the fourth quarter. Stanford Investment Group Inc. now owns 4,329 shares of the biopharmaceutical company’s stock worth $141,000 after buying an additional 456 shares during the last quarter. Finally, Nelson Roberts Investment Advisors LLC raised its stake in Pfizer by 53.1% in the third quarter. Nelson Roberts Investment Advisors LLC now owns 4,590 shares of the biopharmaceutical company’s stock valued at $155,000 after buying an additional 1,591 shares in the last quarter. Institutional investors and hedge funds own 69.53% of the company’s stock.
Shares of Pfizer Inc. (NYSE:PFE) traded down 0.252% on Friday, hitting $33.655. 19,494,559 shares of the company were exchanged. The firm has a market cap of $200.31 billion, a P/E ratio of 28.691 and a beta of 0.94. Pfizer Inc. has a 52-week low of $29.83 and a 52-week high of $37.39. The company has a 50-day moving average price of $34.16 and a 200 day moving average price of $32.82. Pfizer also was the recipient of unusually large options trading on Tuesday. Stock investors acquired 976 call options on the company. This is an increase of approximately 131% compared to the typical daily volume of 422 call options.
Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, January 31st. The biopharmaceutical company reported $0.47 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.50 by $0.03. The company earned $13.60 billion during the quarter, compared to analysts’ expectations of $13.64 billion. Pfizer had a return on equity of 23.18% and a net margin of 13.50%. The company’s revenue for the quarter was down 3.0% compared to the same quarter last year. During the same period in the prior year, the business posted $0.53 EPS. Analysts predict that Pfizer Inc. will post $2.55 EPS for the current fiscal year.
COPYRIGHT VIOLATION WARNING: This news story was first published by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this news story on another publication, it was stolen and reposted in violation of United States & international copyright and trademark law. The legal version of this news story can be accessed at https://sportsperspectives.com/2017/04/21/pfizer-inc-pfe-shares-sold-by-altavista-wealth-management-inc-updated-updated.html.
Several research firms have issued reports on PFE. Zacks Investment Research raised shares of Pfizer from a “hold” rating to a “buy” rating and set a $36.00 price objective on the stock in a report on Tuesday, January 3rd. Barclays PLC set a $38.00 price objective on shares of Pfizer and gave the company a “buy” rating in a report on Thursday, March 16th. Vetr downgraded shares of Pfizer from a “strong-buy” rating to a “buy” rating and set a $35.47 price objective on the stock. in a report on Monday, February 6th. Jefferies Group LLC set a $34.00 price objective on shares of Pfizer and gave the company a “neutral” rating in a report on Friday, February 17th. Finally, Berenberg Bank set a $39.00 price objective on shares of Pfizer and gave the company a “neutral” rating in a report on Friday, February 17th. Thirteen research analysts have rated the stock with a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the company’s stock. Pfizer presently has a consensus rating of “Hold” and a consensus price target of $37.57.
In related news, insider Mikael Dolsten sold 30,970 shares of Pfizer stock in a transaction dated Thursday, March 2nd. The stock was sold at an average price of $34.51, for a total value of $1,068,774.70. Following the transaction, the insider now owns 64,719 shares of the company’s stock, valued at approximately $2,233,452.69. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Rady A. Johnson sold 4,500 shares of Pfizer stock in a transaction dated Friday, March 10th. The stock was sold at an average price of $34.19, for a total value of $153,855.00. Following the completion of the transaction, the insider now directly owns 54,963 shares in the company, valued at approximately $1,879,184.97. The disclosure for this sale can be found here. Insiders sold a total of 71,470 shares of company stock worth $2,449,150 in the last three months. 0.07% of the stock is currently owned by company insiders.
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.